A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to argenx
Related studies linked through entity extraction aliases.
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2/PHASE3
A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy
- Status
- COMPLETED
- Phase
- PHASE2
Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV
- Status
- COMPLETED
- Phase
- PHASE1
ITP Registry and Accompanying Biospecimen Collection
- Status
- RECRUITING
- Phase
- N/A
An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
- Status
- COMPLETED
- Phase
- PHASE3
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis
- Status
- COMPLETED
- Phase
- PHASE3
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Status
- AVAILABLE
- Phase
- N/A
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
- Status
- TERMINATED
- Phase
- PHASE3
A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
- Status
- COMPLETED
- Phase
- PHASE3
A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
SAD and MAD Study With IV and SC Doses of ARGX-117
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)
- Status
- WITHDRAWN
- Phase
- PHASE3